Idiopathic Pulmonary Fibrosis

Fernando J. Martinez, MD, MS


January 24, 2020

Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, and incurable lung disease. Until recently, no medications were known to slow disease progression. In just the past 5 years, two new FDA-approved therapies have been demonstrated to slow progression of IPF as measured by forced vital capacity.

Fortunately, improvement in long-term outcomes can now be achieved by early and accurate diagnosis followed by appropriate treatment. In this ReCAP, Dr Fernando Martinez of Weill Cornell Medicine discusses the diagnosis and treatment options now available for IPF.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.